Wendy Wasserstein, American Playwright

One of America's leading playwrights passed away on Monday. Wendy Wasserstein lost her battle with lymphoma at age 55. The exact type of lymphoma was not released.



The post-feminist icon was very much like the women she wrote about, such as Heidi Holland, the protagonist of The Heidi Chronicles. As she approaches 35, Heidi discovers that she is unfulfilled in her relationships and career. She feels she has been let down or stranded by her generation, which has abandoned its youthful ideals for more traditional values.



Since her first play, Uncommon Women and Others produced in 1975, Wendy Wasserstein has been regarded as the voice of a generation of women who, even today, are caught between their needs to nurture a family and their desire to maintain an intellectual purpose in their lives.



Wendy Wasserstein opened many doors for other artists. Her plays and TV movies were showcases for some of her generation's top actresses - Meryl Streep, Joan Allen, Christine Lahti, and Madeline Kahn. And she founded a theater arts mentoring program for New York City high school students, called Open Doors. Critics, fans and friends agree that Wendy Wasserstein will be remembered as a keen observer of the human condition, a gifted writer, and a trail-blazing artist who contributed much more than plays to the American theater. Voice of America

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap